Incorrect password
evipedia.ai Suggest Edit

Cyanidin-3-Glucoside for Health & Longevity

Evidence Review created on 05/03/2026 using AI4L / Opus 4.7

Also known as: C3G, Chrysanthemin, Kuromanin, Cyanidin-3-O-Glucoside, Cyanidin-3-O-β-D-Glucoside

Motivation

Cyanidin-3-glucoside (C3G or chrysanthemin) is one of the most abundant anthocyanins in the human diet, the natural pigment that gives blackberries, black rice, elderberries, blackcurrants, and purple corn their deep red-to-purple color. It has attracted scientific interest as a candidate compound for cardiovascular protection and metabolic regulation, primarily through its effects on the body’s own antioxidant defenses and on blood vessel function.

Anthocyanin-rich foods have been associated in large observational cohorts with lower cardiovascular disease risk, and standardized extracts – most commonly derived from black rice or bilberry – have been studied for blood pressure, blood lipids, vascular reactivity, and visual function. At the same time, isolated C3G is poorly absorbed in its original form, with most of its activity in the body coming from smaller breakdown products produced by gut bacteria. This combination of dietary prevalence, biological plausibility, and the way the body processes C3G makes it a compound where context matters more than dose.

This review examines the current evidence for C3G as a health and longevity intervention, covering benefits, risks, sourcing, protocols, and the open questions in ongoing research.

Benefits - Risks - Protocol - Conclusion

A curated selection of high-quality resources providing accessible overviews of cyanidin-3-glucoside and the broader anthocyanin family.

  • Berry Extract Improves Night Vision - Kirk Stokel

    Long-form Life Extension Magazine article focused specifically on cyanidin-3-glucoside as a named compound, covering its role in regenerating rhodopsin, age-related decline in night vision, and clinical evidence for acute improvements in dim-light visual function within 30 minutes of dosing.

  • Blueberry Anthocyanins Improve Cardiovascular Health - Rhonda Patrick

    FoundMyFitness Science Digest summary of evidence that isolated blueberry anthocyanins (predominantly cyanidin- and delphinidin-glucosides, with C3G as a major dietary representative) improve flow-mediated dilation and endothelial function comparably to whole-berry intake, framing the cardiovascular case for anthocyanin-rich diets.

  • Health Benefits of Cyanidin-3-Glucoside as a Potent Modulator of Nrf2-Mediated Oxidative Stress - Rahman et al., 2021

    Narrative review concentrated specifically on C3G as a single compound, covering its absorption, gut-microbiota interactions, and Nrf2/ARE (nuclear factor erythroid 2-related factor 2 / antioxidant-responsive element, the master pathway controlling cellular antioxidant defenses) pathway activation. Useful for understanding why C3G’s effects are often disproportionate to its low plasma levels.

  • Recent Advances on Cyanidin-3-O-Glucoside in Preventing Obesity-Related Metabolic Disorders - Oumeddour et al., 2024

    Narrative review focused on C3G’s mechanisms in metabolic disease, covering insulin sensitivity, lipid metabolism, adipose tissue regulation, and the gut-liver axis, with practical context for a longevity-oriented audience.

  • Cyanidin-3-Glucoside: Targeting Atherosclerosis Through Gut Microbiota and Anti-Inflammation - Tang, 2025

    Recent narrative review examining how C3G’s anti-atherosclerotic effects appear to be mediated more through gut microbial reshaping and downstream phenolic metabolites than through direct circulation of the parent molecule.

Note: No dedicated long-form content on C3G or cyanidin-3-glucoside as a named intervention was identified from Peter Attia, Andrew Huberman, or Chris Kresser. Anthocyanins are discussed in passing on these platforms within berry, polyphenol, and gut-microbiome content, but no expert-driven overview specific to isolated C3G was found.

Grokipedia

Chrysanthemin

This Grokipedia article is the dedicated page for cyanidin-3-glucoside (chrysanthemin), covering its chemical identity, biosynthesis, plant sources (berries, black rice, purple corn, hibiscus, soybean seed coats), and biological activities including antioxidant, anti-inflammatory, anticancer, and antidiabetic effects.

Examine

Anthocyanins

Examine’s evidence-based page is the closest dedicated coverage of C3G. It addresses the anthocyanin class as a whole (with C3G as the most abundant dietary member), summarizing graded evidence across cardiovascular health, type 2 diabetes, cognitive function, and inflammation, plus dosing patterns from RCTs (randomized controlled trials).

No dedicated Examine.com page for “cyanidin-3-glucoside” as an isolated supplement was identified.

ConsumerLab

Bilberry Supplements Review

ConsumerLab’s bilberry review is the most directly relevant independent testing of an anthocyanin-rich extract category that is dominated by cyanidin glycosides. Testing found that only 75% of products met label claims, with one supplement containing just 62% of labeled bilberry compounds and another failing disintegration testing – a useful reference for evaluating quality variability across anthocyanin extracts.

No dedicated ConsumerLab review of cyanidin-3-glucoside or black rice anthocyanin extracts as standalone categories was identified.

Systematic Reviews

A selection of the most relevant systematic reviews and meta-analyses covering cyanidin-3-glucoside and the closely related anthocyanin class, where C3G is the dominant dietary representative.

Mechanism of Action

Cyanidin-3-glucoside is the 3-O-β-D-glucoside of cyanidin, a flavylium-cation flavonoid. Its biological effects are best understood as the combined action of (1) the parent C3G molecule acting acutely in the gut and at the gut-blood interface, (2) absorbed C3G and its phase II conjugates (methylated, glucuronidated, and sulfated forms) circulating at low levels, and (3) gut microbiota-derived phenolic acid metabolites, which reach much higher and longer-lasting plasma concentrations than C3G itself.

The principal mechanisms include:

  • Nrf2/ARE pathway activation: C3G and its metabolites activate the nuclear factor erythroid 2-related factor 2 (Nrf2, a master regulator of cellular antioxidant defenses) / antioxidant-responsive element (ARE) signaling axis, upregulating endogenous antioxidant enzymes such as heme oxygenase-1 (HO-1), glutathione peroxidase, and superoxide dismutase rather than acting as a direct antioxidant in the bloodstream.
  • Endothelial nitric oxide signaling: C3G enhances endothelial nitric oxide synthase (eNOS, the enzyme producing NO in blood vessel walls) activity and reduces eNOS uncoupling, increasing nitric oxide (NO) bioavailability and supporting vasodilation and reduced platelet aggregation.
  • Anti-inflammatory NF-κB suppression: C3G inhibits nuclear factor kappa B (NF-κB, a transcription factor that drives inflammatory gene expression), reducing downstream production of TNF-α, IL-6, and adhesion molecules including VCAM-1 and ICAM-1 (intercellular adhesion molecule-1).
  • Insulin and glucose handling: Preclinical and limited human data suggest C3G enhances GLUT4 (glucose transporter 4) translocation in skeletal muscle and adipose tissue, modulates AMPK (AMP-activated protein kinase, a cellular energy sensor) activation, and reduces hepatic lipogenesis.
  • Rhodopsin regeneration: C3G binds directly to rhodopsin (the dim-light visual pigment in retinal rod cells) and accelerates its regeneration after photobleaching, providing a mechanistic basis for acute improvements in dark adaptation.
  • Gut microbiota modulation: Unabsorbed C3G in the colon is metabolized by gut bacteria into protocatechuic acid, vanillic acid, and other phenolic acids, while also reshaping microbial composition toward bile-acid-modifying and short-chain-fatty-acid-producing taxa.

A competing interpretation, increasingly emphasized in recent reviews, is that the parent C3G molecule contributes only modestly to systemic effects: a labeled tracer study found relative bioavailability of approximately 12% (the majority of recovered carbon appearing as phenolic acid metabolites), with metabolites circulating for up to 48 hours. Under this view, “C3G effects” are largely metabolite effects, and outcomes will depend heavily on gut microbiome composition.

C3G is not a pharmaceutical compound, so the standard pharmaceutical descriptors apply only loosely. Plasma half-life of intact C3G is short (roughly 1.5–2 hours after oral dosing), while the half-life of its phenolic acid metabolites ranges from approximately 12 to 52 hours. Tissue distribution favors the kidney, liver, and – after repeated dosing – the brain at low levels. Metabolism is dominated by gut microbial cleavage and hepatic phase II conjugation rather than cytochrome P450 oxidation.

Historical Context & Evolution

Anthocyanins as a chemical class were first characterized in the early 20th century, with the isolation of cyanin and related pigments by Richard Willstätter – work that contributed to his 1915 Nobel Prize in Chemistry. C3G itself was identified as a discrete compound in chrysanthemums (giving rise to the synonym “chrysanthemin”) and later in a wide range of edible plants. Initial interest was botanical and food-technological – understanding plant pigmentation and its stability in food processing – rather than therapeutic.

The shift toward health applications began in earnest in the 1960s with European clinical interest in bilberry extract for visual function, particularly the anecdotal reports from World War II–era British Royal Air Force pilots that bilberry jam improved night vision. Subsequent research linked these effects to anthocyanins, with C3G and related cyanidin glycosides identified as key actors in rhodopsin regeneration. By the 1990s and 2000s, dietary anthocyanin intake was being correlated in large epidemiologic cohorts with reduced cardiovascular disease and type 2 diabetes risk, prompting more targeted clinical research.

A more recent shift has been the move from anthocyanin-rich whole foods (berries, red cabbage, purple sweet potato) to standardized extracts and isolated C3G capsules, primarily from black rice (Oryza sativa) bran. This evolution mirrors the cocoa flavanol field, where standardization enabled clinical-trial replication. The 2013 (13)C-tracer study by Czank and colleagues represented a turning point by demonstrating that anthocyanin bioavailability was substantially higher than previously assumed when phenolic acid metabolites were included, and the 2020s have brought multiple narrative reviews framing C3G’s effects as gut-microbiome-mediated rather than direct. Sports nutrition and bodybuilding communities have also adopted C3G for purported “nutrient partitioning” (a term used to describe selective glucose uptake into muscle versus adipose), although clinical evidence for this specific framing remains limited.

Expected Benefits

High 🟩 🟩 🟩

Improved Vascular Function

Anthocyanin-rich extracts – with C3G as the dominant dietary anthocyanin – improve endothelial function as measured by flow-mediated dilation (FMD), through enhanced nitric oxide bioavailability and reduced eNOS uncoupling. Evidence comes from a meta-analysis of 24 RCTs showing significant acute and chronic improvements in FMD and acute reductions in arterial stiffness. The effect is consistent across acute and chronic dosing.

Magnitude: Acute FMD improvement standardized mean difference (SMD, a statistical measure of effect size) of +3.92% (95% CI [confidence interval] 1.47 to 6.38) and chronic SMD of +0.84% (95% CI 0.55 to 1.12) across 24 RCTs, with concurrent reductions in pulse wave velocity (a measure of arterial stiffness, SMD -1.27 m/s acutely).

Improved Blood Lipid Profile

Anthocyanin supplementation reduces triglycerides and LDL-c while increasing HDL-c in a dose-responsive manner across diverse populations. Evidence comes from a meta-analysis of 41 RCTs in 2,788 participants showing statistically significant improvements across all three lipid endpoints. The effect is most pronounced in dyslipidemic and overweight individuals.

Magnitude: Across 41 RCTs (2,788 participants): triglyceride reduction SMD -0.10 (95% CI -0.18 to -0.01), LDL-c reduction SMD -0.16 (95% CI -0.26 to -0.07), HDL-c increase SMD +0.42 (95% CI +0.20 to +0.65).

Medium 🟩 🟩

Reduced Systemic Inflammation

Anthocyanin intake reduces vascular and systemic inflammatory markers, with the strongest and most consistent effects on endothelial activation markers and weaker effects on classic acute-phase reactants. The effect is mediated through inhibition of NF-κB signaling and reduced production of adhesion molecules in endothelial cells. Evidence comes from a meta-analysis of 16 RCTs, with stronger and more reliable signals in overweight and dyslipidemic populations and at intervention durations of 8–12 weeks or longer.

Magnitude: VCAM-1 reduction of -53.6 ng/mL (95% CI -82.1 to -25.0) across 16 RCTs, with modest non-significant reductions in CRP (-0.27 ng/mL), TNF-α (-0.20 ng/mL), and IL-6 (-0.53 ng/mL); effects strengthen at 8–12 weeks of intervention and in overweight or dyslipidemic populations.

Cardiovascular Disease Risk Reduction (Epidemiologic)

Higher dietary anthocyanin intake is consistently associated with lower incidence of cardiovascular disease, coronary heart disease, and cardiovascular mortality in large prospective cohorts. C3G is the leading contributor to dietary anthocyanin intake.

Magnitude: Linear inverse association across 39 cohorts (1.5 million individuals) – comparing highest to lowest categories of anthocyanin intake yielded an approximately 9% lower risk of cardiovascular disease and approximately 11% lower risk of coronary heart disease.

Improved Cognitive Performance

Multiple RCTs report improvements in verbal and working memory with anthocyanin-rich interventions, supported by neuroimaging-confirmed increases in cerebral blood flow in cognitively relevant brain regions. Evidence comes from a systematic review of 20 RCTs evaluating anthocyanin intake on cognition and vascular endpoints. Effects are most reliable in older adults and at higher doses.

Magnitude: Across 20 RCTs, consistent positive effects on verbal and working memory; a representative trial in older adults found a 19% improvement in working memory accuracy after 12 weeks of 500 mg/day anthocyanin supplementation.

Improved Insulin Sensitivity & Glycemic Control

Anthocyanin supplementation modestly improves fasting glucose, fasting insulin, and HbA1c (glycated hemoglobin, a 3-month average glucose marker) in individuals with type 2 diabetes or metabolic syndrome. The proposed mechanism is enhanced GLUT4 expression in skeletal muscle and adipose tissue together with reduced hepatic gluconeogenesis via AMPK activation. Evidence comes from pooled RCT estimates in dysglycemic populations; effects in metabolically healthy individuals are smaller and inconsistent.

Magnitude: Pooled RCT estimates show fasting glucose reductions in the range of -3 to -6 mg/dL and HbA1c reductions of approximately -0.2 to -0.4 percentage points in dysglycemic populations; effects in metabolically healthy individuals are smaller and inconsistent.

Low 🟩

Improved Dark Adaptation & Night Vision

C3G accelerates rhodopsin regeneration after photobleaching, with small clinical trials reporting acute improvements in dark adaptation and contrast sensitivity. Evidence quality is limited by small sample sizes, and a notable null trial in healthy young adults using freeze-dried blueberries did not replicate the effect.

Magnitude: Acute improvements in dark-adapted visual sensitivity reported within 30 minutes of dosing in small studies of older adults; one placebo-controlled crossover in healthy young adults using blueberry-derived anthocyanins found no measurable effect on dark adaptation.

Reduced Body Fat & Visceral Adiposity ⚠️ Conflicted

C3G has shown effects on adipocyte differentiation, brown adipose tissue activation, and lipid storage in animal models, and a 6-month RCT of standardized blood orange (Moro) extract – enriched in C3G – reported significant reductions in body weight, body mass index, waist and hip circumference, and visceral fat. However, broader anthocyanin-supplementation meta-analyses have not consistently shown body composition effects in mixed populations.

Magnitude: Body weight reduction of 4.2% versus 2.2% in placebo (p = 0.015), waist circumference reduction of 3.9 cm versus 1.7 cm (p = 0.017), and significant visceral fat reduction (p = 0.018) over 6 months of standardized blood orange extract; broader anthocyanin meta-analyses report null or marginal weight effects.

Reduced Liver Fat & NAFLD Markers

Anthocyanin and C3G-rich interventions reduce alanine aminotransferase (ALT, a liver enzyme), aspartate aminotransferase (AST, another liver enzyme), and hepatic fat fraction in non-alcoholic fatty liver disease (NAFLD) populations. The proposed mechanism involves reduced hepatic lipogenesis and improved insulin signaling, alongside attenuation of oxidative stress in hepatocytes. Evidence comes from pooled estimates in polyphenol meta-analyses that include anthocyanin trials; signals are most reliable in NAFLD populations and weaker in metabolically healthy individuals.

Magnitude: Pooled estimates from polyphenol meta-analyses including anthocyanin trials report ALT reductions of approximately -5 to -9 U/L and modest reductions in hepatic fat fraction in NAFLD populations.

Improved Gut Barrier & Microbiome Composition

C3G shifts gut microbiota toward bile-acid-modifying and short-chain fatty acid–producing taxa, reduces intestinal inflammation in inflammatory bowel disease (IBD) models, and improves gut barrier integrity. Direct human evidence is mostly limited to small mechanistic trials.

Magnitude: Not quantified in available studies.

Speculative 🟨

Senescence & Vascular Aging

Preclinical studies suggest C3G may reduce vascular senescence markers and improve endothelial function in aged rats by restoring eNOS coupling and reducing oxidative stress in vascular tissue. Direct human longevity outcomes have not been studied.

Bone Health in Postmenopausal & Diabetic States

Animal studies in diabetic and ovariectomized rats report improvements in bone mineral density and microarchitecture with C3G or black rice anthocyanin supplementation. A recent systematic review of berry polyphenols on bone outcomes is supportive but does not isolate C3G effects.

Skin Photoprotection & Skin Aging

Cell-based studies show C3G reduces UVB-induced damage in keratinocytes and modulates MMP (matrix metalloproteinase, enzymes that degrade collagen) expression. Human topical or oral evidence specific to C3G is preliminary.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in COMT (catechol-O-methyltransferase, an enzyme that methylates catechol-containing compounds including C3G metabolites) and UGT (UDP-glucuronosyltransferase, enzymes responsible for glucuronidation) isoforms influence the rate at which C3G metabolites are cleared, potentially altering tissue exposure. Variants in eNOS may modulate the degree of vascular response to anthocyanin-driven NO signaling.
  • Baseline biomarker levels: Cardiovascular and metabolic benefits are substantially greater in individuals with elevated baseline blood pressure, dyslipidemia, hyperglycemia, or systemic inflammation. People already at optimal levels (normal blood pressure, LDL <100 mg/dL, HbA1c <5.7%) tend to show smaller absolute changes.
  • Sex-based differences: Large RCTs have not consistently identified sex-specific differences in cardiovascular or cognitive responses to anthocyanin supplementation. Some metabolic and body-composition signals (e.g., the Moro orange extract trial) showed similar effects in men and women.
  • Pre-existing health conditions: Individuals with type 2 diabetes, metabolic syndrome, NAFLD, or hypertension appear to derive larger benefits, consistent with greater baseline endothelial dysfunction and oxidative stress. Inflammatory bowel disease populations are an emerging area of interest.
  • Age-related considerations: Older adults (60+) tend to show larger cognitive and vascular benefits, paralleling the cocoa flavanol literature. Age-related reductions in NO bioavailability and increases in low-grade inflammation provide more biological “headroom” for measurable improvement.
  • Gut microbiome composition: Because much of C3G’s bioactivity depends on microbial conversion to phenolic acids (e.g., protocatechuic acid), inter-individual differences in microbiome composition may explain a substantial portion of variability in clinical response. Antibiotic exposure shortly before or during supplementation may blunt effects.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Quality Variability & Adulteration

The greatest practical risk is product variability. Evidence comes from independent third-party testing programs (e.g., ConsumerLab) and botanical authentication studies, which have repeatedly found products substantially below labeled potency or substituted with cheaper plant sources. C3G content per labeled milligram of “black rice extract” varies enormously between manufacturers.

Magnitude: ConsumerLab bilberry testing found that 25% of products failed quality testing, including one product containing only 62% of labeled compounds and another failing disintegration; broader anthocyanin product testing has reported similar or worse rates of label-claim mismatch.

Medium 🟥 🟥

Gastrointestinal Discomfort

Anthocyanin-rich extracts and high-dose C3G can cause mild gastrointestinal effects – nausea, loose stools, or abdominal discomfort – particularly at the start of supplementation or at doses above 500 mg/day. Evidence comes from adverse-event reporting in clinical trials of anthocyanin extracts and pharmacokinetic studies. The effect is typically self-limiting.

Magnitude: Most commonly reported adverse effect in clinical trials of anthocyanin extracts; in the 6-month Moro blood orange RCT, no significant GI adverse-event excess was seen versus placebo. Pharmacokinetic studies of black bean seed coat C3G at moderate doses reported no serious adverse events.

Low 🟥

Increased Bleeding Risk

C3G inhibits platelet aggregation through NO-mediated and PI3K-Akt-pathway (phosphoinositide 3-kinase / protein kinase B, a lipid-kinase signaling cascade regulating cell growth, survival, and platelet activation) mechanisms, potentially increasing bleeding risk when combined with anticoagulant or antiplatelet medications. Evidence comes from in vitro platelet-aggregation assays and ex vivo studies, with limited but consistent signals; clinical bleeding events have not been quantified in RCTs of isolated C3G. Risk at typical supplemental doses appears modest.

Magnitude: Cell and ex vivo studies show measurable platelet inhibition; clinical bleeding events have not been quantified in RCTs of isolated C3G, but the risk pattern parallels other flavonoid-rich extracts.

Hypotension in Treated Hypertensive Individuals

The vasodilatory and blood-pressure (BP)-lowering effects of anthocyanin supplementation may produce additive blood-pressure reduction in individuals already on antihypertensive medication, occasionally causing symptomatic hypotension (lightheadedness on standing). The proposed mechanism is potentiation of nitric-oxide-mediated vasodilation on top of existing pharmacological vasodilation or volume reduction. Evidence comes from pooled RCT estimates of anthocyanin effects on blood pressure in hypertensive populations; the risk is most relevant in older adults on multi-drug regimens.

Magnitude: Pooled BP reductions across anthocyanin RCTs in hypertensive populations are in the range of -3 to -7 mmHg systolic, sufficient to produce additive effects with existing therapy.

Allergy & Hypersensitivity

Allergic reactions to anthocyanin source plants (e.g., berries, soybean, black rice) can occur, though true hypersensitivity to isolated C3G is rare. Evidence comes from case reports and post-marketing observations rather than from controlled trials. Individuals with known berry allergies should exercise caution.

Magnitude: Not quantified in available studies.

Speculative 🟨

Heavy Metal Contamination of Source Material

Black rice and certain berry-derived extracts can carry heavy metal residues (cadmium, arsenic, lead) from soil. Standardized, third-party-tested extracts mitigate this concern, but raw or poorly tested black rice extracts could contribute to long-term exposure.

Hormonal Effects in High-Dose Use

A subset of preclinical studies suggests anthocyanins, including C3G, have weak phytoestrogenic activity at high concentrations. Clinical relevance at typical supplemental doses is unclear and has not been demonstrated in human trials.

Risk-Modifying Factors

  • Genetic polymorphisms: Slow COMT and UGT metabolizers may experience higher tissue exposure to C3G metabolites, potentially amplifying both benefits and any dose-dependent adverse effects. Individuals with pharmacogenomic variants affecting warfarin metabolism (CYP2C9, the cytochrome P450 enzyme that metabolizes warfarin; VKORC1, the gene encoding the enzyme that warfarin inhibits) may need closer INR (international normalized ratio, a measure of blood clotting time) monitoring when adding anthocyanin supplements.
  • Baseline biomarker levels: Individuals with already-low blood pressure (<110/70 mmHg), low platelet count, or elevated bleeding-risk markers (high INR, low fibrinogen) face greater susceptibility to additive hypotension and bleeding.
  • Sex-based differences: No clinically significant sex-based differences in adverse-effect profiles have been identified in trials of anthocyanin extracts. Pregnancy and lactation safety has not been formally established for isolated C3G supplementation.
  • Pre-existing health conditions: Individuals with bleeding disorders, recent surgery, IBD flares, severe kidney disease, or those on multiple cardiovascular medications are at higher relative risk. Allergies to source plants (black rice, berries, hibiscus) should be taken seriously.
  • Age-related considerations: Older adults often have polypharmacy (e.g., aspirin, warfarin, antihypertensives) that increases the risk of additive interactions. Reduced renal clearance in older adults may also increase exposure to phenolic acid metabolites, although clinical relevance is unclear.

Key Interactions & Contraindications

  • Anticoagulants and antiplatelet drugs: C3G can additively inhibit platelet aggregation when combined with warfarin (Coumadin), apixaban (Eliquis), rivaroxaban (Xarelto), clopidogrel (Plavix), or aspirin. Severity: caution; clinical consequence: increased bleeding risk. Mitigation: closer INR monitoring when adding to warfarin therapy; consider holding anthocyanin supplementation 5–7 days before elective surgery.
  • Antihypertensive medications: Additive blood-pressure-lowering effects with ACE inhibitors (lisinopril, enalapril – medications that lower blood pressure by blocking angiotensin-converting enzyme), ARBs (losartan, valsartan – angiotensin receptor blockers), calcium channel blockers (amlodipine), or diuretics. Severity: monitor; clinical consequence: hypotension. Mitigation: home blood pressure monitoring during the first 4 weeks of supplementation.
  • Blood-glucose-lowering drugs and supplements: Modest additive glucose-lowering with metformin, sulfonylureas (glipizide, glyburide), SGLT2 inhibitors (empagliflozin, dapagliflozin – sodium-glucose cotransporter 2 inhibitors), berberine, or alpha-lipoic acid. Severity: monitor; clinical consequence: rare mild hypoglycemia. Mitigation: glucose monitoring in insulin-dependent diabetes.
  • Other antiplatelet supplements: Additive bleeding risk with high-dose fish oil, Ginkgo biloba, garlic extract, vitamin E, and curcumin. Severity: caution.
  • CYP3A4 substrates with narrow therapeutic indices: C3G and related flavonoids have weak CYP3A4-modulating activity in vitro. Severity: theoretical caution; clinical consequence: altered drug levels. Mitigation: spacing dosing from drugs such as tacrolimus or certain chemotherapeutic agents, where clinically appropriate.
  • Populations who should avoid this intervention: Individuals with active major bleeding, planned surgery within 7 days, severe thrombocytopenia (platelet count <50,000/µL), known allergy to the source plant (e.g., black rice, blackberry, blackcurrant), and pregnant or lactating women in the absence of medical guidance, since safety for isolated C3G supplementation has not been established in these populations.

Risk Mitigation Strategies

  • Choose third-party-tested standardized extracts: Select products that publish a Certificate of Analysis (COA) verifying C3G content per capsule and screening for heavy metals (cadmium, lead, arsenic). This addresses the largest practical risk – quality variability.
  • Start low, then titrate: Begin at 60–125 mg/day of standardized C3G (or equivalent anthocyanin dose) for 1–2 weeks before increasing toward the upper studied range of 300–500 mg/day. This reduces the likelihood of GI discomfort and allows assessment of individual tolerance.
  • Take with food and adequate water: Taking C3G with a carbohydrate-containing meal improves systemic exposure (food matrix increases anthocyanin metabolite area-under-the-curve) and reduces the chance of GI upset.
  • Pause before elective surgery: Discontinue C3G supplementation at least 5–7 days before scheduled surgical or dental procedures with bleeding risk, to mitigate antiplatelet effects.
  • Coordinate with anticoagulant therapy: Individuals on warfarin should obtain an INR check 1–2 weeks after adding C3G and again after dose escalation; those on direct oral anticoagulants should monitor for bruising or bleeding signs.
  • Monitor blood pressure during initiation: Hypertensive individuals on medication should self-monitor BP daily for the first 2–4 weeks to detect additive hypotensive effects and adjust antihypertensive doses with their physician if needed.
  • Avoid raw or unverified black rice extracts: Heavy metal accumulation in rice is a documented concern; choose extracts with published heavy metal testing, and avoid bulk powders without verified COAs.
  • Reassess after 3 months: If no measurable change in target biomarkers (BP, lipids, glycemic markers, or qualitative cognitive markers) is observed after 12 weeks at adequate dose, reassess whether continued use is justified.

Therapeutic Protocol

The most well-studied protocols use standardized anthocyanin extracts – most commonly bilberry, blackcurrant, black rice, or standardized blood orange (Moro) extract – rather than purified C3G as a single ingredient. Within these, leading practitioners and clinical trial designs have converged on the following parameters. Researchers prominently associated with this body of work include Aedin Cassidy and Colin Kay (anthocyanin metabolism, University of East Anglia) and Iva Fernandes and Conceição Calhau (bioavailability, Portugal).

  • Standard daily dose: 125–500 mg/day of standardized anthocyanins (with C3G typically constituting 30–80% of total anthocyanin content depending on the source). Black rice extracts marketed as “C3G” supplements are typically dosed at 60–250 mg/day of total anthocyanins, with 6 RCTs and pharmacokinetic studies supporting safety up to 640 mg/day.
  • Best time of day: Morning or early afternoon, taken with a meal. There is no robust evidence of stimulant effects or sleep disruption, but morning dosing aligns with most clinical trial protocols and supports steady daytime levels of phenolic acid metabolites.
  • Half-life: Intact C3G has a short plasma half-life (~1.5–2 hours), but its phenolic acid metabolites circulate for 12–52 hours after a single dose. This long metabolite half-life supports once-daily dosing.
  • Single vs. split dose: Once-daily dosing is sufficient for most outcomes given the long metabolite half-life. Split dosing (morning and afternoon) may be considered for individuals using C3G specifically for visual function (where acute rhodopsin effects matter) or for those experiencing GI discomfort with single larger doses.
  • Genetic considerations: Individuals with COMT Val/Val genotypes (faster catechol metabolism) may benefit from slightly higher or split doses; those with slower UGT activity may achieve adequate exposure at lower doses. Routine genotyping is not necessary.
  • Sex-based differences: No clinically significant dosing differences between men and women have been identified in anthocyanin RCTs.
  • Age-related considerations: Older adults (60+) appear to derive the largest cognitive and vascular benefits and can use the same dose ranges as younger adults. No reduction is needed for age alone.
  • Baseline biomarker considerations: Individuals with baseline hypertension, dyslipidemia, hyperglycemia, or elevated inflammatory markers stand to gain the most. Those with already optimal biomarkers may experience minimal measurable change.
  • Pre-existing health conditions: Individuals with type 2 diabetes, metabolic syndrome, NAFLD, or controlled hypertension can use standard dosing with biomarker monitoring. Those on multi-drug cardiovascular regimens should coordinate with their physician.

Discontinuation & Cycling

C3G and anthocyanin supplementation are generally intended for long-term, daily use as part of a polyphenol-rich dietary or supplement strategy. Existing trials of up to 6–12 months have not identified tolerance, diminishing returns, or chronic safety signals.

There are no known withdrawal effects associated with discontinuing C3G. Vascular and inflammatory benefits will gradually return to baseline over weeks following cessation, paralleling the clearance of phenolic acid metabolites and the loss of induced antioxidant enzyme expression.

  • Lifelong vs. short-term: Long-term, daily use is the dominant pattern in evidence; short courses (e.g., 8–12 weeks for a specific biomarker target) are also reasonable.
  • Withdrawal effects: None reported in published trials.
  • Tapering protocol: Not required; C3G can be stopped abruptly without rebound effects.
  • Cycling: Cycling is not recommended or necessary. C3G acts through substrate-level support of antioxidant defense and gut microbial signaling rather than receptor-binding pathways prone to tolerance.

Sourcing and Quality

Source, purity, and standardization are critical for C3G supplementation, given the wide variability in anthocyanin content and quality between products and source plants.

  • Source material: The most common sources of standardized C3G supplements are black rice (Oryza sativa) bran extract, bilberry (Vaccinium myrtillus) extract, blackcurrant (Ribes nigrum) extract, and elderberry (Sambucus nigra) extract. Black rice extracts typically contain 90%+ of anthocyanins as C3G, while bilberry extracts contain a more diverse mix of cyanidin, delphinidin, and malvidin glycosides.
  • Standardization: Look for products specifying total anthocyanin content (e.g., “standardized to 25% anthocyanins” for bilberry, or “125 mg C3G per capsule” for black rice extract) rather than vague “berry blend” labels. ConsumerLab-style testing of bilberry indicates that “standardized to 36% anthocyanosides” reflects clinical-grade material.
  • Heavy metal testing: Black rice and certain berries can accumulate cadmium, lead, and arsenic. Choose products with publicly available Certificates of Analysis showing heavy metal levels below USP and California Proposition 65 limits.
  • Reputable brands: Brands offering verified C3G content include Nootropics Depot (black rice extract, 125 mg per 2-capsule serving), Life Extension (bilberry-based formulations), and standardized blood orange (Moro) extract products such as those used in the Briskey 2022 RCT. Avoid generic “anthocyanin blend” products without species, extract ratio, or third-party testing data.
  • Form considerations: Capsules and tablets are preferable to powders, since C3G is unstable at high pH, exposed to light, and exposed to oxygen; capsule encapsulation protects against degradation. Liquid extracts should be used quickly after opening.

Practical Considerations

  • Time to effect: Acute effects on rhodopsin regeneration and vascular function (FMD) can occur within 30 minutes to 2 hours of a single dose. Blood pressure and inflammatory marker changes typically emerge within 4–8 weeks of daily supplementation. Lipid profile and glycemic improvements are most reliably observed at 8–12 weeks. Cognitive benefits in older adults have been documented at 12 weeks.
  • Common pitfalls: The most frequent error is conflating “anthocyanin-rich whole food” (e.g., a handful of blueberries) with the C3G doses used in clinical trials – typical dietary intake delivers 10–25 mg/day, while clinical-trial benefits emerge at 100–500 mg/day. Another common error is purchasing unstandardized products without verified C3G content. A third is expecting effects in metabolically healthy individuals at the same magnitude reported in dyslipidemic or hypertensive populations.
  • Regulatory status: C3G and anthocyanin extracts are sold as dietary supplements in the United States and are not approved as drugs for any indication. They are subject to dietary supplement regulations under the Dietary Supplement Health and Education Act (DSHEA) of 1994. There is no FDA qualified health claim for C3G specifically, in contrast to cocoa flavanols.
  • Cost and accessibility: Standardized C3G or black rice extract products typically cost $20–40 per month, comparable to other polyphenol supplements. Bilberry and blackcurrant extracts are similarly priced. Bulk powders are cheaper but less reliable in standardization and stability.

Interaction with Foundational Habits

  • Sleep: No clinically significant effect on sleep has been documented for anthocyanin or C3G supplementation. There is no stimulant content (unlike cocoa flavanols, which contain theobromine and caffeine), and direction of interaction is best characterized as none. Some indirect benefit may accrue through reduced systemic inflammation and improved endothelial function in individuals with sleep-disordered breathing, though this is not well-quantified.
  • Nutrition: C3G is best absorbed with carbohydrate-containing foods; high-fat meals also support absorption of phenolic acid metabolites. The interaction is direct and potentiating with carbohydrate co-ingestion. Anthocyanin-rich diets are highly synergistic with C3G supplementation – adding berries, red cabbage, eggplant skin, and purple sweet potato amplifies total dietary anthocyanin exposure. There is no evidence that C3G depletes specific nutrients. Concurrent consumption of milk proteins (casein) may modestly reduce anthocyanin bioavailability through tannin-protein binding; this is a minor effect.
  • Exercise: C3G supplementation may modestly support post-exercise recovery and vascular adaptation through reduced oxidative stress and improved NO signaling. The interaction with exercise is direct and potentiating for endurance and cardiovascular adaptations. Unlike high-dose vitamin C/E (which can blunt mitochondrial biogenesis adaptations to training), anthocyanins at typical supplemental doses do not appear to interfere with training adaptations and may enhance flow-mediated dilation responses to acute exercise.
  • Stress management: Anthocyanins, including C3G, have been associated with modest improvements in mood and cognitive performance under stress conditions, possibly mediated by improved cerebral blood flow and reduced neuroinflammation. The direction of interaction is indirect potentiation. C3G has not been shown to directly modulate the cortisol stress response in clinically meaningful ways, but its effects on systemic inflammation may benefit individuals with chronic stress-driven elevated CRP or IL-6.

Monitoring Protocol & Defining Success

Baseline assessment and periodic re-testing help quantify individual response to C3G supplementation and ensure ongoing safety, particularly in people with cardiovascular or metabolic conditions.

Baseline testing should be performed within 4 weeks before starting supplementation to establish reliable comparators.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure <120/80 mmHg Track vascular response Resting, seated, average of 2–3 readings; conventional hypertension threshold is ≥130/80
Lipid panel (TC, LDL-c, HDL-c, TG) LDL-c <100 mg/dL, HDL-c >60 mg/dL, TG <100 mg/dL Track lipid response TC = total cholesterol, TG = triglycerides; fasting (12 h); conventional LDL-c target is <130
Fasting glucose 70–85 mg/dL Track glycemic response Fasting (12 h); conventional range is 70–100
HbA1c <5.4% 3-month average glucose Conventional pre-diabetes threshold is 5.7%; not affected by recent meals
Fasting insulin <5 µIU/mL Insulin sensitivity Fasting (12 h); conventional range is 2.6–24.9
hs-CRP <1.0 mg/L Systemic inflammation hs = high-sensitivity assay; conventional considers <3.0 acceptable
ALT / AST ALT <17 U/L (women), <25 U/L (men) Liver function & NAFLD signal Conventional upper limit is 40–45 U/L
INR 0.8–1.2 (untreated); per target if on warfarin Bleeding risk baseline Important if anticoagulation is concurrent

Ongoing monitoring should follow a cadence of 6–8 weeks for the first re-test, then every 3–6 months for the first year, and every 6–12 months thereafter once response is established. Earlier re-testing is appropriate after any dose change.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure <120/80 mmHg Primary vascular response Daily self-monitoring during the first month, then weekly
Lipid panel LDL-c <100 mg/dL, HDL-c >60 mg/dL Track lipid response Every 3–6 months; fasting
Fasting glucose & HbA1c 70–85 mg/dL; HbA1c <5.4% Track glycemic response Every 3–6 months; fasting for glucose
hs-CRP <1.0 mg/L Track inflammation Every 6 months
INR (if on warfarin) Per individualized target Monitor bleeding risk 1–2 weeks after starting and after dose changes

Qualitative markers help capture effects that biomarkers may miss:

  • Self-reported energy and exercise tolerance
  • Subjective cognitive clarity, focus, and verbal recall
  • Sleep quality and dream recall
  • Recovery from physical exertion (delayed-onset muscle soreness)
  • Visual performance in dim conditions (anecdotal but specific to C3G’s mechanism)
  • Skin appearance and elasticity (slow timeframe, 3+ months)

Emerging Research

Several active and recently launched clinical trials, plus a growing mechanistic literature, are expanding the evidence base for C3G and closely related anthocyanin interventions.

  • Bioavailability & kinetics of Aronia melanocarpa (NCT06306911): A recruiting study in 16 healthy young (18–35 years) and older adults (55–75 years) characterizing the bioavailability, kinetics, blood, urine, and fecal metabolite profiles of acute Aronia melanocarpa (chokeberry) extract – one of the highest natural sources of C3G. Results will inform age-specific dosing.

  • Bilberry & oat trial in T2DM (type 2 diabetes mellitus) / MI (myocardial infarction) patients (NCT03620266): A 900-participant active-not-recruiting randomized controlled trial in patients with type 2 diabetes mellitus and/or recent myocardial infarction, comparing dried bilberry, processed oat bran, and combination versus reference, with primary endpoint LDL-c change at 3 months and secondary endpoints including exercise capacity, inflammatory markers, glycemia, and gut microbiota.

  • Polyphenols & exercise in older adults (NCT07441343): A recruiting trial in 40 older adults testing whether 12 weeks of polyphenol supplementation combined with structured resistance and aerobic exercise produces synergistic gains in physical function, muscle health, and inflammation – directly relevant to longevity-oriented use cases.

  • Elderberry-based functional beverage for muscle & gut-muscle axis (NCT07054671): A 54-participant trial of high-purity elderberry anthocyanins (rich in C3G) plus structured exercise, with outcomes spanning gut microbiota composition, short-chain fatty acids, muscle morphology, and exercise performance.

  • Anthocyanin-rich grape powder for postoperative atrial fibrillation prophylaxis (NCT05991700): A Phase 1/2 recruiting trial in 70 cardiac surgery patients evaluating freeze-dried California table grape (anthocyanin-rich) for prevention of postoperative atrial fibrillation through anti-inflammatory and gene-transcription effects – a novel application that could expand the cardiovascular use case.

  • Elderberry anthocyanin gum for cognition & oral microbiota (NCT07054645): A not-yet-recruiting 34-participant trial in older adults with mild cognitive impairment, using a chewing gum formulation of standardized elderberry anthocyanins (cyanidin-3-glucoside and cyanidin-3-sambubioside) to assess cognitive and oral microbiome effects via buccal/sublingual absorption.

  • Mechanistic & metabolite work: Recent narrative reviews (e.g., Tang, 2025 on atherosclerosis through gut microbiota; Oumeddour et al., 2024 on obesity and metabolic disorders) increasingly frame C3G’s effects as primarily mediated through gut microbial reshaping and phenolic-acid metabolites rather than direct circulation of the intact molecule. This reframing could shift dosing strategies, formulation choices (e.g., colon-targeted delivery), and patient-stratification approaches in future trials.

Counter-signal areas of research include studies that have failed to replicate effects (e.g., a 12-week RCT in 90 adults using anthocyanin-rich rice that did not improve cognition or telomere length), which highlight that benefits are not uniform across populations and may require dose, duration, and baseline-risk thresholds not yet fully defined.

Conclusion

Cyanidin-3-glucoside is one of the most studied compounds in the anthocyanin family, and the most abundant anthocyanin in the human diet. The strongest evidence supports modest improvements in vascular function, blood lipids, and inflammatory markers when standardized anthocyanin extracts are taken at clinically meaningful doses. Cognitive benefits, particularly in older adults, are reasonably well-supported, while metabolic and body-composition effects are promising but more variable. Effects on dark adaptation, liver fat, and gut barrier function are biologically plausible but rest on smaller and less consistent human data.

A central nuance is that most clinical evidence comes from anthocyanin-rich whole foods and extract blends rather than purified cyanidin-3-glucoside capsules. The compound is only modestly absorbed in its original form, and most of its activity in the body comes from smaller breakdown products produced by gut bacteria. Benefits therefore depend on the gut microbiome, baseline biomarker status, and dosing duration.

Risks at typical supplemental doses are limited, dominated by quality variability across the supplement market and modest additive effects with anticoagulants and antihypertensive medications. Heavy metal contamination of poorly tested source materials is a real but manageable concern.

For a longevity-oriented audience, the strongest case for cyanidin-3-glucoside supplementation rests on its complementary role within a broader polyphenol-rich diet, its favorable safety profile, and its consistent vascular and inflammatory signal – with the understanding that evidence quality is good for the anthocyanin class as a whole and somewhat thinner for isolated cyanidin-3-glucoside specifically.

Top - Benefits - Risks - Protocol